Introduction {#s1}
============

In current practice, molecular profiling of tumours has become essential to offer targeted therapy for several types of metastasised malignancies. Especially in nonsmall cell lung cancer (NSCLC), targeted therapy has been shown to be highly effective, and multiple tyrosine kinase inhibitors (TKIs) for activating mutations or rearrangements in genes like *EGFR* (epidermal growth factor receptor), *BRAF* (B-Raf proto-oncogene serine/threonine kinase), *ALK* (anaplastic lymphoma kinase) and *ROS1* (Ros oncogene 1 receptor tyrosine kinase) have become available \[[@C1]\]. Also, early detection of resistance mutations like *EGFR* T790M is important as they can guide the next line of therapy \[[@C2]\].

Unfortunately, obtaining tumour tissue for molecular analysis can be challenging. The site of the tumour can be difficult to reach and it often requires invasive procedures to obtain adequate amounts of vital tumour. In this respect, pleural effusion could be an attractive alternative bio-source for molecular analysis, especially as ∼30% of NSCLC patients develop pleural effusion \[[@C3]\]. Usually, DNA is isolated from a cell block or a Giemsa slide, but analysis of cell-free DNA (cfDNA) in the supernatant has shown promising results \[[@C4]--[@C9]\]. Moreover, since the amount of tumour cells or the tumour cell percentage is often insufficient for analysis, this cell-free compartment is highly interesting.

Here, we explore the diagnostic yield of cfDNA analysis in pleural effusion samples from patients with NSCLC and other cancer types for *EGFR* and *KRAS* (KRAS proto-oncogene GTPase) driver mutation detection, as well as for *EGFR* resistance mutations. Analyses of cfDNA from the supernatant were compared head to head with analyses of the cell pellets ([figure 1](#F1){ref-type="fig"}).

![A schematic overview of the collection of pleural effusion. After pleurocentesis the fluid was centrifuged in order to separate the supernatant from the cell pellet.](00016-2019.01){#F1}

Methods {#s2}
=======

Supernatant and corresponding cell pellets from 39 stage IV patients, presented at the Netherlands Cancer Institute (Amsterdam, The Netherlands) between 2009 and 2016, with *EGFR* (n=16) or *KRAS* (n=23) mutation-positive tumours were obtained from the Netherlands Cancer Institute biobank. In total, 44 paired (supernatant and cell pellet) samples were available from 39 patients diagnosed with NSCLC (n=32), colon carcinoma (n=4), appendiceal carcinoma (n=2) and adenocarcinoma of unknown primary (n=1) ([table 1](#TB1){ref-type="table"}). The reason for pleurocentesis was either diagnostic (n=16) or therapeutic (n=28). These samples were leftover material that had been stored as routine laboratory assessment after diagnostics.

###### 

Patient and sample characteristics

                                        **All patients**   **All paired samples**   **Paired samples per tumour driver mutation**          
  ------------------------------------ ------------------ ------------------------ ----------------------------------------------- --- --- ----
  **Patients/samples**                         39                    44                                  15                         4   1   24
  **Tumour type**                                                                                                                          
   Nonsmall cell lung cancer                   32                    35                                  15                         4   1   17
   Colon carcinoma                             4                     4                                                                      4
   Appendiceal carcinoma                       2                     2                                                                      2
   Adenocarcinoma of unknown primary           1                     1                                                                      1

Data are presented as n.

This study was approved by the Institutional Research Board of the Netherlands Cancer Institute (CFMPB497).

All driver gene and *EGFR* T790M mutations were detected in tumour tissue or cytology samples with clinically validated assays using high-resolution melting, fragment analysis, Sanger sequence analysis, MassARRAY technology or next-generation sequencing (NGS) (data not shown). These analyses were done in multiple hospitals in the Netherlands.

The supernatant was separated from the cell pellet after centrifugation (1700×*g* for 10 min). The pellet was resuspended in 0.5 mL of 0.9% NaCl. Both samples were stored at −30°C. In total, 400 μL from the cell pellet was isolated using the QIAsymphony DSP DNA Midi Kit (Qiagen, Hilden, Germany). At least 10% from the sample was analysed, from a median eluted volume of 200 μL. cfDNA was isolated from a median (range) of 1 (0.75--4) mL pleural effusion using the QIAsymphony Circulating DNA kit (Qiagen). At least 20% of the sample was analysed, from a median eluted volume of 90 μL. The Bio-Rad (Hercules, CA, USA) QX200 droplet digital PCR (ddPCR) was used for mutation detection using Bio-Rad PrimePCR ddPCR mutation assays for *KRAS* (*KRAS* Screening Multiplex 186-3506), *EGFR* T790M (dHsaCP2000019 and dHsaCP2000020), *EGFR* exon 19 deletion screening assay \[[@C10]\], *EGFR* L858R (dHsaCP2000021 and dHsaCP2000022) and *EGFR* G719X (validated laboratory-developed method using IDT (Coralville, IA, USA) *EGFR* wild-type for G719 (HEX), *EGFR* G719S and *EGFR* G719A (both FAM)). The limit of blank and the limit of detection were determined for each individual assay using a Clinical and Laboratory Standards Institute (CLSI) EP17 protocol \[[@C11]\]. Results were analysed using Quantasoft version 1.6.6 ([www.quantasoft.com](http://www.quantasoft.com)). Supernatant results were normalised to the amount of cfDNA in 1 mL of fluid.

Results {#s3}
=======

The majority of the 44 paired samples were either both positive (30 out of 44) or both negative (eight out of 44) for the original driver mutation. In five cases the driver mutation was only detected in the supernatant and in one case only in the cell pellet ([table 2](#TB2){ref-type="table"}). Thus, in 36 of the 44 paired samples a driver mutation was detected using both the supernatant and the cell pellet. Testing only the supernatant would detect 35 of the 36 drivers (97%) and analysis of only the cell pellet would detect 31 of the 36 drivers (86%). These results indicated that the supernatant was an excellent bio-source for ddPCR driver detection. Optimal sensitivity was reached when both the cell pellet and supernatant were analysed.

###### 

Detection of original driver mutations by droplet digital PCR in paired samples (supernatant and cell pellet available) of pleural effusions

  **Supernatant**        **Cell pellet**       
  --------------------- ----------------- ---- ----
  **Driver positive**          30          5    35
  **Driver negative**           1          8    9
  **Total**                    31          13   44

Data are presented as n.

In five paired samples the driver mutation was only detected in the supernatant. Reviewing the cytology reports for these cases showed that in two of these samples no tumour cells were seen, in two cases no cytologically analysis was performed and in one case the tumour cell percentage was only 1%. In four of these cell pellets no mutant copies were found and in one the amount was below the limit of detection. In one sample only the cell pellet was positive for the primary driver mutation. This cell pellet had a very low estimated tumour cell percentage and a borderline result of only 1 mutant copy·μL^−1^ in the cell pellet ([supplementary table S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00016-2019.figures-only#fig-data-supplementary-materials)). No mutant copies were detected in the supernatant by ddPCR. The cfDNA was isolated from 0.75 mL of supernatant and showed a very low concentration of 0.005 ng·μL^−1^ measured by Qubit (Invitrogen, Carlsbad, CA, USA). Therefore, the mutation could easily be missed in our analysis.

To evaluate whether pleural effusion could be used as a bio-source for resistance analysis after progression on *EGFR* TKIs we analysed 20 paired pleural effusions sampled from the 16 patients with *EGFR*-positive tumours for the presence of *EGFR* T790M. *EGFR* T790M was detected in seven out of the 20 paired samples. All seven supernatants and cell pellets were positive ([table 3](#TB3){ref-type="table"}). Four out of the seven *EGFR* T790M mutation-positive pleural effusion samples had very low estimated tumour cell percentages and in one case no tumour cells were seen by the pathologist ([supplementary table S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00016-2019.figures-only#fig-data-supplementary-materials)). Five of the seven pleural effusions were sampled from patients progressing on first-generation *EGFR* TKIs (erlotinib, gefitinib). Furthermore, two cases with a positive supernatant, but with a cell pellet showing a borderline result of 1 copy·μL^−1^, identified two patients with a durable response to osimertinib. The cytology reports of these pleural effusion samples showed that in one sample no tumour cells were seen and in one sample the tumour cell percentage was very low ([supplementary table S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00016-2019.figures-only#fig-data-supplementary-materials)). These results indicated that the supernatant is a good bio-source to detect *EGFR* T790M. In four patients *EGFR* T790M had already been detected in tumour tissue samples by clinically validated diagnostic assays. *EGFR* T790M was confirmed in all four matched supernatants and cell pellets. Two out of the seven samples were initially taken specifically for molecular resistance analysis by NGS/TSACP version 1.0 (MiSeq; Illumina, San Diego, CA, USA) using the cell pellet: in one of these samples NGS could be successfully performed but no T790M mutation was found, while for the other sample in the end no NGS was done due to a low estimated tumour cell percentage. Both samples had tumour cell percentages ≤5% ([supplementary table S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00016-2019.figures-only#fig-data-supplementary-materials)).

###### 

Detection of *EGFR* T790M by droplet digital PCR in paired samples (supernatant and cell pellet available) of pleural effusions

  **Supernatant**       **Cell pellet**       
  -------------------- ----------------- ---- ----
  **T790M positive**           7          0    7
  **T790M negative**           0          13   13
  **Total**                    7          13   20

Data are presented as n.

Discussion {#s4}
==========

This study investigated whether cfDNA from the supernatant of pleural effusions could be used for detecting driver mutations and *EGFR* resistance mutations. Our results clearly show that the cell-free fraction of pleural effusions is an excellent source for cfDNA and that it can be used to detect driver as well as resistance mutations effectively with ddPCR. We showed a high concordance rate between the supernatant and the cell pellet, which is in line with a previous study \[[@C6]\], but a slightly lower rate has been reported elsewhere \[[@C7]\]. Furthermore, our results suggest that by using cfDNA in pleural effusion as a bio-source, the molecular testing has gained in sensitivity, and that optimal sensitivity can be reached by analysing both the supernatant and the cell pellet. In addition to analysis of cfDNA in pleural effusion from NSCLC patients, we could also detect *KRAS* mutations in the supernatant samples from patients with colon carcinoma, appendiceal carcinoma and adenocarcinoma of unknown primary, which has not been reported before.

In five pleural effusion samples driver mutations were detected only in the supernatant even though no or very few tumour cells were seen in the cytopathological results. In our study, mutations were only called when the amount of copies found by ddPCR was above the limit of detection, determined according to the CLSI EP17 protocol \[[@C11]\]. The limit of detection was set with a confidence level of 99% to prevent false-positive results. Tumour DNA in the five corresponding cell pellets was not present or too low to detect the driver mutation. Importantly, since the detection of a driver mutation in the supernatant provides no proof of actual presence of tumour cells it can at present not be used for staging purposes. The origin of cfDNA in the supernatant has not been well studied, although several theories have been described \[[@C5], [@C8], [@C9]\]. Most likely this cfDNA is released from necrotic cells in the pleural cavity, but may also have been leaked from the circulation as a transudate. Alternatively, the cfDNA could have been derived from tumour cells damaged in the pre-analytical phase, *e.g.* by centrifugation \[[@C5]\], or from exosomes secreted by the tumour \[[@C8], [@C9]\]. Therefore, a high detection rate in the supernatant is expected and also observed in our study. In one pleural effusion sample only the cell pellet was positive for the driver mutation. Most likely too little tumour DNA was present in the supernatant.

Resistance mutations are subclonal events in the tumour that often occur during TKI treatment. The *EGFR* T790M mutation, for example, is common in tumours of patients progressing on first-generation *EGFR* TKIs (erlotinib, gefitinib) \[[@C2]\]. Osimertinib is frequently given as alternative treatment after this mutation is detected in a biopsy of a progressive lesion \[[@C2]\]. As obtaining tumour tissue is challenging and *EGFR* T790M is a subclonal event, sensitive techniques are needed for molecular testing. Plasma genotyping is an alternative approach, but the sensitivity of detecting *EGFR* T790M in plasma is only 70% \[[@C12]\]. Therefore, other bio-sources for molecular testing could be useful. In our study, seven paired samples were positive for *EGFR* T790M, of which all were concordant between the supernatant and the cell pellet. Based on these results, both the supernatant and the cell pellet performed equally well as bio-sources for detecting *EGFR* T790M. The pleural effusion samples from four of the five patients progressing on first-generation *EGFR* TKIs showed a higher amount of T790M copies in both the supernatant and cell pellet compared with the two patients showing a durable response to osimertinib. In prospective studies it will be interesting to see if the amount of *EGFR* T790M copies, measured by ddPCR in the supernatant and cell pellet of pleural effusions, correlates to outcome in patients with *EGFR*-positive tumours treated with osimertinib.

This study is limited by the small sample size. The supernatant performed better as a bio-source than the cell pellet for detecting *EGFR* or *KRAS* primary driver mutations, but not for detecting *EGFR* T790M. Studies with a larger sample size are needed to confirm our results. Besides this, we could only compare a subset of the paired samples with results obtained in molecular diagnostics with NGS/TSACP version 1.0 using the cell pellet. A direct comparison with a larger set of paired samples could confirm the additive value of using cfDNA in the supernatant as a bio-source for molecular profiling in a clinical setting.

In conclusion, we showed that analysis of cfDNA in pleural effusion can robustly detect *EGFR* and *KRAS* driver mutations and *EGFR* resistance mutations. Therefore, cfDNA is a valuable bio-source for molecular testing, even when tumour cell purity is low.
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